Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India.

Autor: Das S; Department of Transfusion Medicine, All India Institute of Medical Sciences, Nagpur, Maharashtra, India.; Department of Transfusion Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Kayal S; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Dubashi B; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India., Basavarajegowda A; Department of Transfusion Medicine, All India Institute of Medical Sciences, Nagpur, Maharashtra, India., Pasupala NK; Department of Transfusion Medicine, All India Institute of Medical Sciences, Nagpur, Maharashtra, India.; Department of Transfusion Medicine, Yashoda Superspecialty Hospital, Somajiguda, Hyderabad, India., Kulkarni R; Department of Transfusion Medicine, All India Institute of Medical Sciences, Nagpur, Maharashtra, India., Dhanraju K; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.; Medical Oncology, American Oncology Institute, Guntur, Andhra Pradesh, India., Pani CK; Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.; Medical Oncology, Apollo Hospital, Bhubaneswar, Odisha, India.
Jazyk: angličtina
Zdroj: Asian journal of transfusion science [Asian J Transfus Sci] 2022 Jan-Jun; Vol. 16 (1), pp. 7-14. Date of Electronic Publication: 2022 Jul 30.
DOI: 10.4103/ajts.ajts_106_21
Abstrakt: Background: Plerixafor is used for patients at risk of Stem cell mobilization failure based on clinical factors or low peripheral blood CD34 count. It is also added upfront to any mobilization irrespective of risk factor, but the cost-effectiveness of the approach is an issue. Data on plerixafor in different settings of autologous hematopoietic stem cell (HSC) collection from India are scant. We are hereby reporting the experience of failure/success of mobilization rate and few important significant variables (CD34+ dosage, failed collection) between plerixafor and granulocyte colony-stimulating factor alone groups among autologous hematopoietic stem cell transplantation (aHSCT) at our institute.
Methods: This was a record-based single-center study on patients who underwent aHSCT from January 2013 to June 2019 at a tertiary care hospital. Descriptive statistics were used for baseline characteristics, transplant-related factors, and peritransplant outcomes. All statistical analyses were performed at the 5% significance level.
Results: During the study duration, a total of 96 patients had undergone autologous hematopoietic stem cell collection (aHSCC), all by peripheral blood stem cell harvest, requiring 131 apheretic collections. Of the total 131 collections in 96 patients, plerixafor was used in 63 apheresis collections (48% of total pheresis) in 40 patients. Among the 40 patients who were administered plerixafor to augment the collection, 34 patients had upfront use of plerixafor. We did not observe any significant adverse event related to plerixafor use.
Conclusion: A rational utilization of plerixafor can facilitate the process and logistics of aHSCC outcome.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2022 Asian Journal of Transfusion Science.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje